MAXINOVEL HONGKONG LIMITED

We are an innovation-driven biopharmaceutical company headquartered in China with a global vision, dedicated to discovering and developing small-molecule ackbone therapies for oncology and immunology indications. Enabled by our integrated Small Molecule Backbone Drug R&D Platform and strategically guided by clinical practice guidelines, we focus on advancing novel backbone small molecule therapies with synergistic mechanisms to existing standards of care, aiming to develop globally IP protected